45 Recruiting HER2-positive Breast Cancer Clinical Trials
Explore open interventional and observational research studies actively enrolling participants across the USA. Verify eligibility and contact site coordinators directly.
📍 Find Near Me by DistanceBrowse by State
Browse by Study Phase
Top Interventions for HER2-positive Breast Cancer
Related Conditions
Top Recruiting HER2-positive Breast Cancer Studies
Radiation Therapy Followed by Intrathecal Trastuzumab/Pertuzumab in HER2+ Breast Leptomeningeal Disease
📍 Moffitt Cancer Center — Tampa, Florida
View Study & Checklist ➔Neoadjuvant Her2-targeted Therapy and Immunotherapy With Pembrolizumab [IIT2018-04-MCARTHUR-NEOHP]
📍 Cedars Sinai Medical Center — Los Angeles, California
View Study & Checklist ➔ELVN-002 With Trastuzumab +/- Chemotherapy in HER2+ Solid Tumors, Colorectal and Breast Cancer
📍 BRCR Medical Center Inc. — Plantation, Florida
View Study & Checklist ➔PHESGO Maintenance After T-DXd Short Induction for HER2+ Unresectable Locally Recurrent or Metastatic Breast Cancer
📍 Dana-Farber Cancer Institute — Boston, Massachusetts
View Study & Checklist ➔A Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer
📍 University of South Alabama Health Children's and Women's Hospital — Mobile, Alabama
View Study & Checklist ➔A Single Arm Phase II Study of ADjuvant Endocrine Therapy, Pertuzumab, and Trastuzumab for Patients With Anatomic Stage I Hormone Receptor-positive, HER2-positive Breast Cancer
📍 Stamford Hospital — Stamford, Connecticut
View Study & Checklist ➔Omission of Radiation in Patients With Her-2 Positive Breast Cancer
📍 University of Kansas Medical Center/ Cancer Center — Kansas City, Kansas
View Study & Checklist ➔Testing Radiation and HER2-targeted Therapy Versus HER2-targeted Therapy Alone for Low-risk HER2-positive Breast Cancer
📍 Cancer Center at Saint Joseph's — Phoenix, Arizona
View Study & Checklist ➔Clinical Trial of Atezolizumab With Paclitaxel, Trastuzumab, and Pertuzumab in Patients With Metastatic HER-2 Positive Breast Cancer
📍 Fox Chase Cancer Center — Philadelphia, Pennsylvania
View Study & Checklist ➔Study of HER2 Directed Dendritic Cell (DC1) Vaccine + Weekly Paclitaxel, Trastuzumab & Pertuzumab
📍 Moffitt Cancer Center — Tampa, Florida
View Study & Checklist ➔PRE-I-SPY Phase I/Ib Oncology Platform Program
📍 The University of Alabama at Birmingham O'Neal Comprehensive Cancer Center — Birmingham, Alabama
View Study & Checklist ➔Tucatinib, Trastuzumab and Capecitabine With Brain and/or Spinal Radiotherapy (XRT) in Patients With HER2+, HER2 Mutated and/or HER2-amplified Metastatic Breast Cancer and Leptomeningeal Disease: A Multi-centre Phase II, Single Arm Feasibility Study
📍 The Ottawa Hospital — Ottawa, Ontario
View Study & Checklist ➔RO7771950 Versus Tucatinib in Combination With Trastuzumab and Capecitabine in People With Locally Advanced or Metastatic Breast Cancer That is Human Epidermal Growth Factor Receptor 2 (HER2)-Positive
📍 The West Clinic, PC dba West Cancer Center — Germantown, Tennessee
View Study & Checklist ➔Prolonged Overnight Fasting and/or Exercise on Fatigue and Other Patient Reported Outcomes in Women With Hormone Receptor Positive Advanced Breast Cancer
📍 Arizona State University — Phoenix, Arizona
View Study & Checklist ➔Monitoring HER2+ Breast Cancer Neoadjuvant Treatment With Advanced PET/MRI
📍 The University of Alabama at Birmingham — Birmingham, Alabama
View Study & Checklist ➔A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer
📍 Oncology Institute — Long Beach, California
View Study & Checklist ➔